NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NRx Pharmaceuticals Presentation at NobleCon21 and Company Overview
TL;DR
NRx Pharmaceuticals' presentation at NobleCon21 offers investors insights into clinical revenue progress and expanded focus on treatments for suicidal depression and PTSD.
NRx Pharmaceuticals will present updates on investigational drugs like NRX-100 and NRX-101, detailing clinical progress and regulatory filings for CNS disorder treatments.
NRx Pharmaceuticals' expanded focus on suicidal depression and PTSD treatments represents progress toward better mental health outcomes and reduced suffering worldwide.
NRx Pharmaceuticals' CEO will discuss their NMDA platform drugs that have received Fast Track and Breakthrough Therapy designations for treating suicidal depression.
Found this article helpful?
Share it with your network and spread the knowledge!
NRx Pharmaceuticals' Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H. will present at NobleCon21 on December 3, 2025, offering updates on the company's expanded focus in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions.
The presentation will take place on December 3, 2025 at 4:30 p.m. EST at NobleCon21.
Jonathan Javitt, M.D., M.P.H., the Founder, Chairman and CEO of NRx Pharmaceuticals, will be presenting.
NRx Pharmaceuticals focuses on treating central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD.
NRX-100 is preservative-free intravenous ketamine that has received Fast Track Designation for treating Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 is oral D-cycloserine/lurasidone that has received Breakthrough Therapy Designation for treating suicidal bipolar depression.
NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for treating suicidal depression.
The full press release can be viewed at https://ibn.fm/JeaP1, and more information about the company is available at www.nrxpharma.com.
Forward-looking statements involve risks, uncertainties, and factors that may cause actual results to differ materially, and undue reliance should not be placed on them when making investment decisions. These statements are based on information available as of the date of the announcement and are subject to risks detailed in the company's SEC filings.
The presentation will provide updates on the company's expanded focus areas and progress in generating clinical revenue since NobleCon 2024, offering insights into their development pipeline and business progress.
Curated from NewMediaWire
